Yang Zhi-Wei, Xu Ge-Liang
Department of General Surgery, Heilongjiang Provincial Hospital, Harbin 150036, China.
Hepatobiliary Pancreat Dis Int. 2004 Feb;3(1):12-6.
Many treatments have been proposed for non-resectable primary or secondary hepatic cancer but the results have been disappointing. Isolated hepatic perfusion (IHP) was attempted five decades ago but it has been accepted recently after spectacular tumour responses were obtained by several phase I-II trials.
An English-language literature search using MEDLINE (2003), Index Medicus (2003) and bibliographic reviews of books and review articles. IHP and its history and recent clinical application.
IHP offers unique pharmacokinetic advantages for locoregional chemotherapy and biotherapy. Surgical isolation of the liver and percutaneous techniques using balloon occlusion catheters are reliable and safe. They appear to have significant efficacy even in patients with advanced tumor burden or those with tumors refractory to other types of therapy.
IHP which has been developed in recent years is becoming a promising strategy for the treatment of unresectable liver cancer.
对于不可切除的原发性或继发性肝癌，已经提出了许多治疗方法，但结果令人失望。五十年前就尝试过孤立肝灌注（IHP），但在几项I-II期试验取得显著的肿瘤反应后，最近才被接受。
使用MEDLINE（2003年）、医学索引（2003年）以及书籍和综述文章的书目综述进行英文文献检索。IHP及其历史和近期临床应用。
IHP为局部区域化疗和生物治疗提供了独特的药代动力学优势。肝脏的手术隔离和使用球囊闭塞导管的经皮技术可靠且安全。即使对于肿瘤负荷晚期或对其他类型治疗难治的肿瘤患者，它们似乎也有显著疗效。
近年来发展起来的IHP正成为治疗不可切除肝癌的一种有前景的策略。
Zotero 插件